Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

dverse event (13.8% versus 16.0%).

-- Across the Contrave Phase 3 trial experience to date, only 7.6% of all reported adverse events led to an early discontinuation from the trials.

In summary, naltrexone SR met its primary objectives by providing a lower peak plasma concentration (Cmax) than the legacy IR formulation while retaining a similar total plasma exposure (AUC). This held true both for the parent molecule (naltrexone) and its principal active metabolite (6-beta-naltrexol). In a Phase I pilot study, improved tolerability was suggested amongst those who received naltrexone SR / bupropion SR than those receiving the prior Phase 2 formulation containing naltrexone IR. Finally, in a blinded, pooled analysis of preliminary Phase 3 data, results suggest that naltrexone SR / bupropion SR may be associated with decreased rates of treatment-emergent nausea, headache, dizziness, or discontinuation due to an adverse event.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

About Contrave(R)

Contrave is an investigational weight loss medication with a mechanism of action that works at two sites within the central nervous system. The first is a hypothalamic site that controls the balanc
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PARK CITY, Utah , Sept. 17, 2014 ... into an exclusive global licensing and collaboration agreement ... develop and commercialize NuView,s investigative genomic-based diagnostic biomarker ... The agreement also includes all other future diagnostic-imaging ... compound for in-vivo therapeutic delivery and in-vitro urine ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. ... today announced a partnership in the fight against ... the Sarcoma Alliance Suzanne Renee Leider Memorial Assistance ... financial assistance to reimburse sarcoma patients for expenses ... a sarcoma specialist. Scientific literature reinforces the importance ...
Breaking Medicine Technology:NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
... , BOSTON, Nov. 23 AMICAS, Inc. ... management solutions, today announced that it will highlight its enterprise ... America (RSNA) annual meeting from November 29 to December 4 ... in booth #7124. , (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) ...
... , MINNEAPOLIS, Nov. 23 BridgePoint Medical announced ... for its coronary and peripheral Chronic Total Occlusion (CTO) ... and the Stingray® CTO Re-Entry System. The BridgePoint ... designed to navigate highly diseased arteries in preparation for ...
Cached Medicine Technology:AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 2AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 3BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 2BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 3
(Date:9/17/2014)... 2014 Promising new research published in ... light on the potential ability of ketones to support ... The study shows that brain hypometabolism ... by impaired glucose uptake and/or utilization, and results suggest ... , The study, by the Research Center on Aging ...
(Date:9/17/2014)... September 16, 2014) A study led by ... the chemotherapy dose threshold below which male childhood ... production. The study appears in September 17 edition ... By clarifying which patients are at highest risk ... the findings to eventually increase use of pre-treatment ...
(Date:9/17/2014)... wine leads to an explosion of flavours in your mouth. ... that can mimic what happens in your mouth when you ... of dryness in the wine. , When wine growers turn ... of processes to bring out the desired flavour in the ... part of the taste is known in wine terminology as ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A  recent ... of a 24-year-old man named Advait Thakur who had ... caused by degenerative disc disease. This disease led to ... his nerve roots and causing severe pain. Leading spine ... and how it can lead to such severe pain, ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
Breaking Medicine News(10 mins):Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 3Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3
... By Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... phone use and texting soared in the space of three ... Texting alone caused more than 16,000 deaths in car accidents ... involving cell phones and texting while driving rose 28 percent ...
... S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, ... will help protect the safety of over 900,000 Canadians ... day. The Canadian Patient Safety Institute and its ... research competition drawing some of Canada,s leading healthcare researchers. ...
... Reporter , THURSDAY, Sept. 23 (HealthDay News) -- It was ... dream. He,d just been plucked from his life as ... the National Basketball Association,s Dallas Mavericks, summer training camp after ... But a small on-court collision with another player led to ...
... to boost research on women,s health over the last two ... among women due to cardiovascular disease, breast cancer, and cervical ... The effort has yielded less but still significant progress ... women, added the committee that wrote the report. ...
... pathology at the University of California, San Diego School ... the Moores UCSD Cancer Center, has been named the ... bestowed by the Metastasis Research Society, an international, non-profit ... was honored at a recent joint meeting of the ...
... and Tallinn, Estonia (September 23, 2010) At an international ... Global TB Vaccine Foundation announced it will initiate a clinical ... led by researchers at Saint Louis University in St. Louis, ... Global Forum on TB Vaccine Development. Building on ...
Cached Medicine News:Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 3Health News:Experimental Leukemia Drug Proves a Slam Dunk 4Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 2Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 3Health News:David Cheresh receives top award for cancer metastasis research 2Health News:New TB vaccine enters clinical testing 2
Bipolar gingivoplasty loop. Individual sterile packs....
The Hilan pneumatic high speed drill system consists of a pneumatic motor and drill with various cutting attachments....
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
Medicine Products: